Literature DB >> 32160919

Left colon as a novel high-risk factor for postoperative recurrence of stage II colon cancer.

Liming Wang1, Yasumitsu Hirano2, Toshimasa Ishii2, Hiroka Kondo2, Kiyoka Hara2, Nao Obara2, Shigeki Yamaguchi2.   

Abstract

BACKGROUND: It is not clear whether stage II colon and rectal cancer have the same risk factors for recurrence. Thus, the purpose of this study was to identify the risk factors for postoperative recurrence in stage II colorectal cancer. PATIENTS AND METHODS: We retrospectively analyzed the data of 990 patients who had undergone radical surgery for stage II colorectal cancer. Patients' pathological features and characteristics including age, sex, family history, body mass index, tumor diameter, gross type of tumor, infiltration degree (T3/T4), tumor grade, perineural invasion, vascular invasion, lymphatic invasion, pathologic examination of lymph node number, and preoperative carcinoembryonic assay (CEA) level was compared between patients with and without recurrence. Finally, the prediction of the left and right colons was analyzed.
RESULTS: The mean ages of the colon cancer and rectal cancer patients were 69.5 years and 66.4 years, respectively. In total, 508 (82.1%) and 285 (76.8%) patients were treated laparoscopically for colon cancer and rectal cancer, respectively, with median follow-up periods of 42.2 months and 41.8 months, respectively. Forty-four recurrences occurred in both the colon cancer (7.1%) and rectal cancer (11.9%) groups. The preoperative serum CEA level and T4 infiltration were significantly higher in recurrent colorectal cancer patients. The postoperative recurrence rate of left colon cancer (descending colon, sigmoid colon) was higher than that of right colon cancer (cecum, ascending colon, transverse colon) (OR 2.191, 95% CI 1.091-4.400, P = 0.027). In COX survival factor analysis of colon cancer, the left colon is one of the independent risk factors (risk ratio 5.377, 95% CI 0.216-0.88, P = 0.02). In disease-free survival (DFS), the left colon has a relatively poor prognosis (P = 0.05). However, in the COX analysis and prognosis analysis of OS, no difference was found between the left colon and the right colon.
CONCLUSION: Preoperative CEA and depth of infiltration (T4) are high-risk factors associated with recurrence and are prognostic factors in stage II colorectal cancer. Left colon is also a risk factor for postoperative recurrence of stage II colon cancer.

Entities:  

Keywords:  Carcinoembryonic antigen; Colorectal cancer; Left colon cancer; Stage II

Mesh:

Substances:

Year:  2020        PMID: 32160919      PMCID: PMC7066772          DOI: 10.1186/s12957-020-01818-7

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


Colorectal cancer (CRC) is one of the most common cancers and a leading cause of cancer-related death in men and women [1]. CRC is also a major cause of death in Japan, being the leading cause in women and the third most common cause in men [2]. The efficacy of adjuvant chemotherapy for stage II CRC remains controversial, although the benefit of adjuvant chemotherapy for stage III CRC has been established [3-6]. Many studies have reported that rectal cancer differs from colon cancer in etiology, genetics, clinical manifestation, anatomy, and biological characteristics [7], but it is unclear whether stage II colon and rectal cancer have the same risk factors for recurrence. The purpose of this study was to identify the risk factors for postoperative recurrence in stage II colorectal cancer.

Patients and methods

We retrospectively analyzed the clinical data of 990 patients with stage II CRC in the Division of Gastroenterological Surgery of Saitama Medical University from 2007 to 2016. The surgery was considered therapeutic when there was no macroscopic or microscopic residual cancer after surgery. There were 579 men and 411 women, comprising 619 patients with colon cancer and 371 patients with rectal cancer. Patients receiving preoperative treatment or presenting with intestinal obstruction or perforation were excluded from the analysis. Peripheral blood samples were collected before surgery. The serum CEA level was determined by radioimmunoassay. The CEA level was considered high at ≥ 5 ng/ml. The resected specimens were pathologically classified according to the 7th edition of the Union for International Cancer Control TNM classification of malignant tumors. All patients underwent follow up with regular physical and blood examinations, colonoscopy, and computed tomography. All statistical analyses were performed using the SPSS software package version 22.0 for Macintosh (IBM Japan, Tokyo, Japan). The significance of the correlations between the preoperative CEA level and the pathological features was analyzed using the chi-squared test for independence according to each parameter. In order to control for confounding factors, binary logistic regression was used. Wald test was used to evaluate the significance of the association. Survival curves were plotted with the Kaplan–Meier method and analyzed with a log-rank test. P < 0.05 was considered statistically significant.

Results

Clinical characteristics of CRCs

As shown in Table 1, a total of 990 CRC patients were included, comprising 371 with rectal cancer and 619 with colon cancer. The mean ages of colon cancer and rectal cancer patients were 69.5 years and 66.4 years, respectively. Of these, 508 (82.1%) of the colon cancer patients and 285 (76.8%) of the rectal cancer patients were treated laparoscopically. The median follow-up periods were 42.2 months for colon cancer and 41.8 months for rectal cancer. Forty-four recurrences occurred in both the colon cancer (7.1%) and rectal cancer (11.9%) groups. We observed significant differences between the colon and rectal cancer patients regarding sex, average age, postoperative recurrence rate, gross type, serum CEA levels, and vascular invasion (all P < 0.05). Other features were not significantly different, including open or laparoscopic methods, differentiation, invasion depth (T), perineural invasion, cancer diameter, and infiltration of lymphatic vessels.
Table 1

Clinicopathological parameters in stage II colon and rectal cancer

Clinicopathological ParametersRectal cancerColon cancerP value
Gender (Total n=)371 (100.00%)619 (100.00%)
 Male245 (66.04%)334 (53.96%)
 Female126 (33.96%)285 (46.04%)<0.01
Age (year)66.4±0.5569.5±0.42<0.01
Post Operation Recurrence
 No327 (88.14%)574 (92.73%)
 Yes44 (11.86%)44 (7.11%)0.011
Open or Laparoscopic
 Open86 (23.18%)113 (18.26%)
 Laparoscopic285 (76.82%)508 (82.07%)0.059
Gross Type
 Protruding18 (4.85%)56 (9.05%)
 Ulcerative & Infiltratie353 (95.15%)563 (90.95%)0.015
 Diameter (cm)5.44±0.115.24±0.100.105
Differentiation
 Well & Moderate354 (95.42%)581 (93.86%)
 Poor & Mucinous17 (4.58%)38 (6.14%)0.37
T
 T3329 (89.648%)536 (87.39%)
 T439 (10.51%)78 (12.60%)0.324
CEA (ng/mL)
 <5192 (51.75%)400 (64.62%)
 ≥5179 (48.25%)219 (35.38%)<0.01
Number of dissected lymph nodes
 <1259 (15.90%)71 (11.47%)
 ≥12312 (84.10%)548 (88.53%)0.05
Perineural Invasion
 No316 (85.18%)523 (84.49%)
 Yes55 (14.82%)96 (15.51%)0.77
Vascular Invasion
 No318 (85.71%)263 (42.49%)
 Yes53 (14.29%)356 (57.51%)<0.01
Infiltration lymphatic vessels
 No312 (84.10%)501 (80.94%)
 Yes59 (15.90%)118 (19.06%)0.24
Clinicopathological parameters in stage II colon and rectal cancer

Comparisons of clinicopathological parameters between CRC recurrence and non-recurrence

Rectal cancer recurrence was associated with a body mass index greater than 25 kg/m2 (P = 0.0001), a larger tumor size (6.00 ± 0.34; P < 0.001), advanced T stage (P < 0.005), higher serum CEA levels (P < 0.002), poor differentiation or mucinous histology (P < 0.007), perineural invasion (P < 0.001), vascular invasion (P = 0.028), and infiltration of lymphatic vessels (P < 0.001) (Table 2).
Table 2

Clinicopathological parameters for rectal cancer recurrence and non-recurrence

Clinicopathological ParametersRectal Non-RecurrenceRectal RecurrenceP value
Gender (Total n=)327 (100.00%)44 (100.00%)
 Male216 (66.06%)29 (65.91%)
 Female111 (33.94%)15 (34.09%)0.88
Age (year)66.35±1.3265.7±0.550.30
Cancer Familly History
 None140 (42.81%)22 (50.00%)
 Yes187 (57.19%)22 (50.00%)0.45
BMI
 <25309 (94.50%)34 (77.27%)
 ≥2518 (5.50%)10 (22.73%)0.0001
Duplicate cancer
 None298 (91.13%)38 (86.36%)
 Yes29 (8.87%)6 (13.64%)0.45
Multiple Cancer
 None308 (94.19%)38 (86.36%)
 Yes19 (5.81%)6 (13.64%)0.104
Post Appendectomy
 None266 (81.35%)37 (84.09%)
 Yes61 (18.65%)7 (15.91%)0.81
Gross Type
 Protruding20 (6.12%)2 (4.55%)
 Ulcerative & Infiltratie307 (93.88%)42 (95.45%)0.94
 Diameter (cm)5.42±0.116.00±0.340.045
Differentiation
 Well & Moderate316 (96.64%)38 (86.36%)
 Poor & Mucinous11 (3.36%)6 (13.64%)0.007
T
 T3298 (91.15%)30 (68.17%)
 T429 (8.85%)14 (31.82%)0.005
CEA (ng/mL)
 <5187 (57.19%)14 (31.82%)
 ≥5140 (42.81%)30 (68.18%)0.002
Number of dissected lymph nodes
 <1254 (16.51%)6 (13.64%)
 ≥12273 (83.49%)38 (86.36%)0.78
Perineural Invasion(0.00%)
 No49 (14.98%)37 (84.09%)
 Yes278 (85.02%)7 (15.91%)<0.001
Vascular Invasion
 No118 (36.09%)8 (18.18%)
 Yes209 (63.91%)36 (81.82%)0.028
Infiltration lymphatic vessels
 No291 (88.99%)29 (65.91%)
 Yes36 (11.01%)15 (34.09%)<0.001
Clinicopathological parameters for rectal cancer recurrence and non-recurrence Compared with rectal cancer, colon cancer recurrence was associated with just an advanced T stage (P < 0.0001) and higher serum CEA levels (P = 0.009) (Table 3).
Table 3

Clinicopathological parameters for colon cancer recurrence and non-recurrence

Clinicopathological ParametersColon Non-RecurrenceColon RecurrenceP value
Gender (Total n=)575 (100.00%)44 (100.00%)
 Male309 (53.74%)24 (54.55%)
 Female266 (46.26%)20 (45.45%)0.95
Age (year)69.7±0.4370.32±1.730.35
Cancer Familly History
 None272 (47.30%)19 (43.18%)
 Yes303 (52.70%)25 (56.82%)0.71
BMI
 <25448 (77.91%)36 (81.82%)
 ≥25127 (22.09%)8 (18.18%)0.67
Duplicate cancer
 None493 (85.74%)40 (90.91%)
 Yes82 (14.26%)4 (9.09%)0.46
Multiple Cancer
 None543 (94.43%)42 (95.45%)
 Yes32 (5.57%)2 (4.55%)0.95
Tumor location
 Left colon278 (48.34% )27( 61.37%)
 Right colon297 (51.65%)17 (38.63% )0.09
Gross Type
 Protruding51 (8.87%)1 (2.27%)
 Ulcerative & Infiltratie524 (91.13%)43 (97.73%)0.21
 Diameter (cm)5.2±0.105.45±0.480.25
Differentiation
 Well & Moderate527 (91.65%)37 (84.09%)
 Poor & Mucinous48 (8.35%)7 (15.91%)0.15
T
 T3511 (88.8%)30 (68.18%)
 T464 (11.2%)14 (31.82%)<0.0001
CEA (ng/mL)
 <5380 (66.09%)20 (45.45%)
 ≥5195 (33.91%)24 (54.55%)0.009
Number of dissected lymph nodes
 <1268 (11.83%)4 (9.09%)
 ≥12507 (88.17%)40 (90.91%)0.76
Perineural Invasion(0.00%)
 No494 (85.91%)40 (90.91%)
 Yes81 (14.09%)4 (9.09%)0.48
Vascular Invasion
 No250 (43.48%)13 (29.55%)
 Yes325 (56.52%)31 (70.45%)0.1
Infiltration lymphatic vessels
 No469 (81.57%)35 (79.55%)
 Yes106 (18.43%)9 (20.45%)0.89
Clinicopathological parameters for colon cancer recurrence and non-recurrence

Correlations between the preoperative CEA levels and the site of recurrence

Local recurrences were significantly more common for rectal cancers with a higher CEA level than for those with a lower CEA level (P < 0.05). However, there was no significant difference in liver metastasis, lung metastasis, or peritoneal spread between the two groups (Table 4).
Table 4

Correlations between the preoperative CEA levels and the site of recurrence in stage II rectal cancer and colon cancer

Rectal Cancer CEA ( ng/ml)Colon Cancer CEA ( ng/ml)
CEA<5CEA ≥5p-ValueCEA <5CEA ≥5p-Value
n = 191n = 170n = 389n = 219
Liver metastasis
 Negative187 (97.91%)161 (94.71%)381 (97.94%)209 (95.43%)
 Positive4 (2.09%)9 (5.29%)0.108 (2.06%)10 (4.57%)0.07
Lung metastasis
 Negative187 (97.91%)163 (95.88%)384 (98.71%)214 (97.72%)
 Positive4 (2.09%)7 (4.12%)0.265 (1.29%)5 (2.28%)0.35
Local recurrence
 Negative185 (96.08%)157 (92.35%)384 (98.71%)213 (97.26%)
 Positive6 (3.92%)13 (7.65%)0.0285 (1.29%)6 (2.74%)0.96
Peritoneal dissemination
 Negative190 (99.48%)169 (99.41%)386 (99.23%)213 (97.26%)
 Positive1 (0.52%)1 (0.59%)0.933 (0.77%)6 (2.74%)0.053
Correlations between the preoperative CEA levels and the site of recurrence in stage II rectal cancer and colon cancer Although the patients with higher CEA levels were more likely to develop colon cancer recurrence, there was no significant difference in the site of recurrence (Table 4).

Correlations between the depth of infiltration and the site of recurrence

Local recurrences were significantly more common for colorectal cancers with T4 infiltration than for those with T3 infiltration (both P < 0.05) (Table 5). There was a higher rate of lung metastasis recurrence in patients with T4 rectal cancer compared with T3 (P = 0.004). In patients with T4 colon cancer, there was a higher rate of peritoneal metastasis (P = 0.014).
Table 5

Correlations between the depth of infiltration and the site of recurrence in stage II rectal cancer and colon cancer

Rectal CancerColon Cancer
T3T4p-ValueT3T4p-Value
n = 332n = 39n = 542n = 77
Liver metastasis
 Negative320 (96.39%)38 (97.44%)526 (97.05%)74 (96.10%)
 Positive12 (3.61%)1 (2.56%)0.73516 (2.95%)3 (3.90%)0.651
Lung metastasis
 Negative325 (97.89%)35 (89.74%)535 (98.71%)74 (96.10%)
 Positive7 (2.11%)4 (10.26%)0.0047 (1.29%)3 (3.90%)0.089
Local recurrence
 Negative318 (95.78%)34 (87.18%)534 (98.52%)70 (90.91%)
 Positive14 (4.22%)5 (12.82%)0.0218 (1.48%)7 (9.09%)<0.001
Peritoneal dissemination
 Negative331 (99.70%)38 (97.44%)538 (99.26%)74 (96.10%)
 Positive1 (0.30%)1 (2.56%)0.0674 (0.74%)3 (3.90%)0.014
Correlations between the depth of infiltration and the site of recurrence in stage II rectal cancer and colon cancer In multivariate analysis, a higher CEA level was associated with a higher chance of recurrence of both rectal cancer (odds ratio [OR] 1.011, 95% confidence interval [95% CI] 1.00–1.021, P = 0.048) and colon cancer (OR 1.010 95% CI 1.003–1.017, P = 0.004). In addition, T4 cancer had a higher chance of recurrence in both rectal cancer (OR 3.867, 95% CI 1.547–9.663, P = 0.004) and colon cancer (OR 3.222, 95% CI 1.238–8.390, P = 0.017) (Table 6). In colon cancer, the postoperative recurrence rate of left colon cancer (descending colon, sigmoid colon) was higher than that of right colon cancer (cecum, ascending colon, transverse colon) (OR 2.191, 95% CI 1.091–4.400, P = 0.027). However, there was no significant difference between low rectal cancer and upper rectal cancer.
Table 6

Multivariate logistic regression analysis evaluating possible risk factors associated with recurrence

Rectal CancerColon Cancer
Odds ratio95% CIpOdds ratio95% CIp
Gender1.2590.587-2.700.5540.8790.453- 1.7040.702
Age, year0.9830.953 -1.0140.2701.0170.985-1.0500.300
T4 vs T33.8671.547-9.6630.0043.2221.238-8.3900.017
CEA (ng/mL)1.0111.000-1.0210.0481.0101.003 -1.0170.004
Tumor locationRb vs Ra, RSLeft colon vs Right colon
0.8250.411- 1.6510.5892.1911. 091-4.4000.027

Tumor location*: Rectal cancer (Rb & Ra, RS). Ra rectum above the peritoneal reflection, Rb rectum below the peritoneal reflection, RS rectosigmoid. Colon cancer: Left colon (Descending colon, sigmoid colon) & Right colon( Cecum, ascending colon, transverse colon)

Multivariate logistic regression analysis evaluating possible risk factors associated with recurrence Tumor location*: Rectal cancer (Rb & Ra, RS). Ra rectum above the peritoneal reflection, Rb rectum below the peritoneal reflection, RS rectosigmoid. Colon cancer: Left colon (Descending colon, sigmoid colon) & Right colon( Cecum, ascending colon, transverse colon)

Correlations of the preoperative CEA levels and depth of infiltration with the survival rate

The overall survival rate was significantly lower in both colon and rectal cancer patients with high levels of CEA and in T4 patients (P = 0.005, 0.006, 0.0044, and 0.006, respectively) (Figs. 1a, b and 2a, b). High levels of serum CEA and T4 reduced the disease-free survival (P = 0.005, 0.001, 0.000, and 0.000) (Figs. 3a, b and 4a, b).
Fig. 1

Survival outcomes for colorectal cancer patients with CEA ≧ 5 vs. CEA < 5

Fig. 2

Survival outcomes for colorectal cancer patients with T3 vs. T4

Fig. 3

Disease-free survival for colorectal cancer patients with CEA ≧ 5 vs. CEA < 5

Fig. 4

Disease-free survival for colorectal cancer patients with T3 vs. T4

Survival outcomes for colorectal cancer patients with CEA ≧ 5 vs. CEA < 5 Survival outcomes for colorectal cancer patients with T3 vs. T4 Disease-free survival for colorectal cancer patients with CEA ≧ 5 vs. CEA < 5 Disease-free survival for colorectal cancer patients with T3 vs. T4

Prognostic differences between the left colon and the right colon

To compare the prognosis of histological parameters determined in univariate analysis, Cox’s proportional hazard regression model was applied. For DFS, left colon, vascular invasion, infiltrating pattern, and T4 were all shown to be independent risk factors. For OS, signet ring cell carcinoma, mucinous carcinoma, poorly differentiated carcinoma, vascular invasion, infiltrating pattern etc. were shown to be independent risk factors (Table 7). For the DFS Kaplan-Meier survival curve, the left colon also has a relatively poor prognosis. However, in the OS curve, there is no difference between the left colon and the right colon (Fig. 5a, b). There is no statistical difference in the ratio of T4:T3 (P = 0.337) and CEA ≥ 5 ng/ml (P = 0.32) in left colon cancer and right colon cancer (detailed data not shown).
Table 7

Cox proportional hazard regression model comparing the effects of different parameters on the prognosis of patients with stage II Colon cancer

ADC adenocarcinoma, CEA carcinoembryonic antigen, CI confidence interval, SRC signet ring cell carcinoma, HR hazard ratio, Poor poor poorly differentiated adenocarcinoma, INF Infiltrating pattern of invasion, INFa Swelling proliferation, INF c Invasive proliferation, INF b between a and c. vs. versus, Left colon(Descending colon, sigmoid colon); Right colon( Cecum, ascending colon, transverse colon)

Fig 5

Prognosis of left colon cancer vs. right colon cancer

Cox proportional hazard regression model comparing the effects of different parameters on the prognosis of patients with stage II Colon cancer ADC adenocarcinoma, CEA carcinoembryonic antigen, CI confidence interval, SRC signet ring cell carcinoma, HR hazard ratio, Poor poor poorly differentiated adenocarcinoma, INF Infiltrating pattern of invasion, INFa Swelling proliferation, INF c Invasive proliferation, INF b between a and c. vs. versus, Left colon(Descending colon, sigmoid colon); Right colon( Cecum, ascending colon, transverse colon) Prognosis of left colon cancer vs. right colon cancer

Discussion

The question of whether colon and rectal cancer should be treated as a single entity or as two separate entities remains controversial [8]. The treatment of stage II CRCs has also been extensively debated [7, 9]. Our findings indicate that these two groups show considerable differences in many clinic-pathological characteristics. Significant differences were seen between the two groups in sex, average age, postoperative recurrence, gross type, surgical procedure (open/laparoscopic), serum CEA level, and vascular invasion. Therefore, our results showed that, in stage II CRC, the characteristics of colon cancer and rectal cancer were different, which is why they should be considered two separate entities. Out of 4,244 primary CRC patients, 990 cases (23.3%) of stage II CRC were found in our hospital in the past 10 years. In view of the different characteristics of rectal cancer and colon cancer, we independently analyzed their relapse characteristics. The depth of infiltration and level of the preoperative tumor marker CEA were directly related to recurrence in the colon cancer recurrence group compared with the non-recurrence group. This is consistent with the results of another study [10]. However, rectal cancer recurrence is much more complicated. It was not only related to the serum CEA level and depth of infiltration, but also obesity, tumor size, tumor type, and postoperative pathological lymphatic infiltration and perineural invasion. Therefore, CEA level and depth of infiltration are the common factors for the recurrence of the stage II CRC. These results are largely consistent with those of another study that also found that CEA and CA19-9 were factors associated with recurrence [11, 12]. We then looked at whether CEA was associated with the site of tumor recurrence. Although CEA is a complex glycoprotein that is the most commonly used tumor marker for CRC, it is highly nonspecific. In colon cancer, we did not find any relationship between CEA and the location of tumor recurrence but it was significantly associated with the local recurrence of rectal cancer. Local recurrence of rectal cancer involves lymph nodes near the sacrum, lymph nodes around the great arteries, and lateral lymph nodes. In this study, the preoperative CEA level and depth of infiltration (T4) were risk factors and prognostic factors for recurrence of stage II colon cancer. The different biological characteristics between rectal cancer and colon cancer lead to diverse recurrence factors and prognostic factors. We found that the incidence of postoperative recurrence for left colon cancer was higher than that of right, and left colon is one of the independent risk factors of poorer DFS, which was consistent with some reports [13, 14]. The majority of the literature differs, reporting that there is no difference [15] or that the right colon has a relatively poor prognosis [16-19]. The inclusion of the rectum in the left colon is the biggest difference between these reports. This study also shows that many biological characteristics of the colon and rectum are different. The distinction between the descending colon and the sigmoid colon from the rectum may be more conducive to future treatment. But more surprisingly, there was no difference in OS between the left colon and the right colon. This may be because the left colon, when compared with the right colon, even though RAS/BRAF are wild-type, has more advantages in the choice of chemotherapy drugs cetuximab or panitumumab [20]. It is important to recognize the limitations of this study. The chemotherapy effect of CRC is closely related to KRAS and BRAF gene mutations or microsatellite instability (MSI) [21]. In future analysis, research on genetic components needs to be strengthened. Second, this study is a single-center retrospective study with a relatively small sample size, and we look forward to future multi-center clinical studies.

Conclusion

Our results indicate that the preoperative CEA level and depth of infiltration (T4) are high-risk factors associated with recurrence and are prognostic factors in stage II colorectal cancer. Left colon is also a risk factor for the postoperative recurrence of stage II colon cancer, and special attention should be paid during follow-up.
  21 in total

1.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Hiroya Takiuchi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2011-10-15       Impact factor: 3.402

Review 2.  Vascular invasion, perineural invasion, and tumour budding: predictors of outcome in colorectal cancer.

Authors:  Johannes Betge; Cord Langner
Journal:  Acta Gastroenterol Belg       Date:  2011-12       Impact factor: 1.316

3.  Clinical and prognostic differences between surgically resected right-sided and left-sided colorectal cancer.

Authors:  Koji Fukata; Norihiro Yuasa; Eiji Takeuchi; Hideo Miyake; Hidemasa Nagai; Yuichiro Yoshioka; Kanji Miyata
Journal:  Surg Today       Date:  2019-10-14       Impact factor: 2.549

4.  Meta-analysis of the molecular associations of mucinous colorectal cancer.

Authors:  I S Reynolds; S J Furney; E W Kay; D A McNamara; J H M Prehn; J P Burke
Journal:  Br J Surg       Date:  2019-04-04       Impact factor: 6.939

5.  Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline.

Authors:  B M Meyers; R Cosby; F Quereshy; D Jonker
Journal:  Curr Oncol       Date:  2016-12-21       Impact factor: 3.677

6.  Outcome of patients with clinical stage II or III rectal cancer treated without adjuvant radiotherapy.

Authors:  Shin Fujita; Seiichiro Yamamoto; Takayuki Akasu; Yoshihiro Moriya
Journal:  Int J Colorectal Dis       Date:  2008-07-02       Impact factor: 2.571

7.  Descriptive epidemiology of colorectal cancer.

Authors:  P Boyle; D G Zaridze; M Smans
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  Comparison of 627 patients with right- and left-sided colon cancer in China: Differences in clinicopathology, recurrence, and survival.

Authors:  Qiong Qin; Lin Yang; Yong-Kun Sun; Jian-Ming Ying; Yan Song; Wen Zhang; Jin-Wan Wang; Ai-Ping Zhou
Journal:  Chronic Dis Transl Med       Date:  2017-03-13

10.  Impact of tumor sidedness on survival and recurrence patterns in colon cancer patients.

Authors:  Jong Min Lee; Yoon Dae Han; Min Soo Cho; Hyuk Hur; Byung Soh Min; Kang Young Lee; Nam Kyu Kim
Journal:  Ann Surg Treat Res       Date:  2019-05-29       Impact factor: 1.859

View more
  5 in total

1.  Postoperative locoregional recurrence pattern and treatment management of stage pT4 sigmoid colon cancer: a retrospective cohort study.

Authors:  Yaobin Lin; Shan Liu; Liang Hong; Lingdong Shao; Junxin Wu
Journal:  Radiat Oncol       Date:  2022-05-13       Impact factor: 4.309

2.  Prognostic analysis and beneficiary identification of adjuvant external beam radiotherapy for stage pT4b sigmoid colon cancer.

Authors:  Yaobin Lin; Lei Wang; Lingdong Shao; Xueqing Zhang; Huaqin Lin; Youjia Wang; Junxin Wu
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

3.  A retrospective study based on SEER database: not all high-risk factors are equal for stage II colon cancer.

Authors:  Dong Li; Zongze Jiang; Lili Xiang; Chuanhua Yang; Feiwu Long; Wenneng Liu
Journal:  Transl Cancer Res       Date:  2022-04       Impact factor: 1.241

4.  Prognostic significance of additional histologic features for subclassification of pathological T3 colon cancer.

Authors:  Lorenzo Macchi; Quoc Riccardo Bao; Laura Albertoni; Matteo Fassan; Valentina Chiminazzo; Marco Scarpa; Gaya Spolverato; Salvatore Pucciarelli
Journal:  Int J Clin Oncol       Date:  2022-06-18       Impact factor: 3.850

5.  Serum zinc level and tissue ZIP4 expression are related to the prognosis of patients with stages I-III colon cancer.

Authors:  Xin Wu; Han Wu; Liyang Liu; Guanghui Qiang; Jianwei Zhu
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.